Investigational New Drugs

Journal

Overview
Identity

Publication Venue For

Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. 37:473-481. 2019

Randomized phase II trial of neoadjuvant everolimus in patients with high-risk localized prostate cancer. 37:559-566. 2019

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML). 31:1023-1034. 2013

Dietary supplementation of silymarin protects against chemically induced nephrotoxicity, inflammation and renal tumor promotion response. 28:703-713. 2010

FBA-TPQ, a novel marine-derived compound as experimental therapy for prostate cancer. 28:234-241. 2010

Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. 25:565-570. 2007

A phase I clinical and pharmacological profile of dacarbazine with autologous bone marrow transplantation in patients with solid tumors. 11:169-179. 1993

Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer. 11:61-65. 1993

A phase II trial of CI-921 in advanced malignancies. 10:309-312. 1992

International Standard Serial Number (issn)

0167-6997

Electronic International Standard Serial Number (eissn)

1573-0646